Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: De novo donor specific antibodies (dnDSA) occur in up to 50% of lung transplant (LUTX) recipients within one year and are associated with increased risk for antibody-mediated rejection (AMR). HLA eplet mismatch is a risk factor for dnDSA development; however not all patients with dnDSA progress to AMR. We hypothesize cytomegalovirus (CMV) viremia in the setting of increased HLA eplet mismatch (MM) load exerts a synergistic effect on risk for AMR.
*Methods: HLA typing was performed using low resolution rSSO Luminex assay. HLAMatchmaker was used to compute Class I and II HLA Eplet MM load. HLA antibody testing by SAB was performed at evaluation, LUTX, and post-TX surveillance and clinical time points. CMV mismatch and R+ recipients received prophylaxis with ganciclovir or valganciclovir. Patients who developed CMV disease or viremia detected by PCR were considered CMV+. Primary endpoint was defined as AMR precipitating clinical intervention. Secondary endpoints included dnDSA and all-cause mortality at 1 year.
*Results: 126 adult patients underwent LUTX at Baylor University Medical Center between June 2013 and December 2016; 9 were excluded from the analysis for re-transplant (n=1), death within 30 days (n=4), incomplete HLA testing (n=3), and CMV viremia detected before TX (n=1). Of the 117 patients included, 42 (36%) were CMV+ and 75 (64%) were CMV-. Clinical AMR developed in 14/42 (33%) CMV+ and 9/75 (12%) CMV- patients. Patients in the AMR+ group had a higher Class II HLA Eplet MM load (27 vs 22; p=0.01) and developed dnDSA earlier (mean 330 vs 612 days; p=0.01). Also, development of AMR was associated with increased risk for mortality at 1 year (OR 4.94; p=0.001). When stratified by CMV status, Class II HLA Eplet MM was associated with increased risk for AMR (Tables 1 and 2).
|POS||Class I||0.96||0.87 – 1.06||0.42|
|POS||Class II||1.08||1.00 – 1.17||0.04|
|POS||Class I+II||1.04||0.98 – 1.10||0.22|
|NEG||Class I||1.04||0.92 – 1.18||0.54|
|NEG||Class II||1.04||0.97 – 1.11||0.31|
|NEG||Class I+II||1.04||0.98 – 1.10||0.23|
|POS||Class I||0.81||0.49 – 1.34||0.42|
|POS||Class II||1.48||1.00 – 2.19||0.04|
|POS||Class I+II||1.20||0.90 – 1.62||0.22|
|NEG||Class I||1.22||0.65 – 2.31||0.54|
|NEG||Class II||1.20||0.85 – 1.68||0.31|
|NEG||Class I+II||1.19||0.90 – 1.59||0.23|
*Conclusions: CMV viremia in the setting of high Class II HLA Eplet mismatch load increases risk for developing clinical AMR in lung transplant recipients.
To cite this abstract in AMA style:Im Y, Yeramaneni S, Yim Y, Dodderer J, Askar M, Huang HJ. Synergistic Effect of HLA Eplet Mismatch Load and CMV Viremia on Clinical Antibody-Mediated Rejection in Lung Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/synergistic-effect-of-hla-eplet-mismatch-load-and-cmv-viremia-on-clinical-antibody-mediated-rejection-in-lung-transplantation/. Accessed June 13, 2021.
« Back to 2019 American Transplant Congress